RAPT - RAPT Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
RAPT price evolution
RAPT
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $37.08 | $45.32 | $47.48 | |
| Short term investments | $77.76 | $96.26 | $111.38 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $102.6 | $120.5 | $148.36 | $161.78 |
| Long term investments | ||||
| Property, plant & equipment | $5.48 | $6.24 | $7.01 | $7.68 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $6.68 | $7.46 | $11.55 | |
| Total investments | $77.76 | $96.26 | $111.38 | |
| Total assets | $108.47 | $127.18 | $155.82 | $173.33 |
| Current liabilities | ||||
| Accounts payable | $1.38 | $2.72 | $6.77 | $5.18 |
| Deferred revenue | ||||
| Short long term debt | $2.57 | $2.51 | $2.45 | |
| Total current liabilities | $10.36 | $14.8 | $21.17 | $21.84 |
| Long term debt | $3.16 | $3.81 | $4.46 | |
| Total noncurrent liabilities | $3.16 | $3.81 | $4.46 | |
| Total debt | $5.73 | $6.32 | $6.91 | |
| Total liabilities | $12.96 | $17.96 | $24.98 | $26.29 |
| Shareholders' equity | ||||
| Retained earnings | -$561.3 | -$542.87 | -$515.2 | -$484.68 |
| Other shareholder equity | $0.11 | -$0.05 | -$0.01 | $0.1 |
| Total shareholder equity | $109.22 | $130.84 | $147.03 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $47.48 | $38.95 | $24.03 | $24.92 |
| Short term investments | $111.38 | $210.12 | $165.63 | $86.59 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $161.78 | $252.69 | $192.97 | $115.6 |
| Long term investments | ||||
| Property, plant & equipment | $7.68 | $9.48 | $2.74 | $2.98 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $11.55 | $13.52 | $5.66 | $3.37 |
| Total investments | $111.38 | $210.12 | $165.63 | $86.59 |
| Total assets | $173.33 | $266.21 | $198.64 | $118.97 |
| Current liabilities | ||||
| Accounts payable | $5.18 | $3.37 | $2 | $2.38 |
| Deferred revenue | $1.53 | $4.96 | ||
| Short long term debt | $2.45 | $2.17 | ||
| Total current liabilities | $21.84 | $14.22 | $9.6 | $11.74 |
| Long term debt | $4.46 | $6.82 | ||
| Total noncurrent liabilities | $4.46 | $6.82 | $2.66 | $3.05 |
| Total debt | $6.91 | $8.99 | ||
| Total liabilities | $26.29 | $21.04 | $12.26 | $14.79 |
| Shareholders' equity | ||||
| Retained earnings | -$484.68 | -$367.88 | -$284.05 | -$214.84 |
| Other shareholder equity | $0.1 | -$0.03 | -$0.21 | -$0.18 |
| Total shareholder equity | $147.03 | $245.17 | $186.38 | $104.18 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $22.64 | $24.78 | $26.76 | |
| Selling, general & administrative | $6.69 | $7.74 | $6.45 | |
| Total operating expenses | $29.33 | $32.52 | $33.22 | |
| Operating income | -$29.33 | -$32.52 | -$33.22 | |
| Income from continuing operations | ||||
| EBIT | -$27.66 | -$30.52 | -$30.88 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$27.66 | -$30.52 | -$30.88 | |
| Income (for common shares) | -$27.66 | -$30.52 | -$30.88 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.53 | $3.81 | $5.04 | |
| Cost of revenue | ||||
| Gross Profit | $1.53 | $3.81 | $5.04 | |
| Operating activities | ||||
| Research & development | $101 | $67.08 | $56.98 | $45.48 |
| Selling, general & administrative | $26.06 | $20.24 | $16.04 | $12.77 |
| Total operating expenses | $127.06 | $87.32 | $73.02 | $58.26 |
| Operating income | -$127.06 | -$85.8 | -$69.21 | -$53.21 |
| Income from continuing operations | ||||
| EBIT | -$116.8 | -$83.84 | -$69.2 | -$51.9 |
| Income tax expense | $0.99 | |||
| Interest expense | ||||
| Net income | ||||
| Net income | -$116.8 | -$83.84 | -$69.2 | -$52.89 |
| Income (for common shares) | -$116.8 | -$83.84 | -$69.2 | -$52.89 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$27.66 | -$30.52 | -$30.88 | |
| Operating activities | ||||
| Depreciation | $0.89 | $0.9 | $0.91 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.38 | $5.4 | $4.43 | |
| Total cash flows from operations | -$28.15 | -$27.08 | -$27.75 | |
| Investing activities | ||||
| Capital expenditures | $0 | -$0.1 | -$0.07 | |
| Investments | $19.21 | $15.99 | $20.71 | |
| Total cash flows from investing | $53.55 | $19.21 | $15.89 | $20.64 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.7 | $9.04 | $0.46 | |
| Net borrowings | ||||
| Total cash flows from financing | $9.74 | $0.7 | $9.04 | $0.46 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$9.58 | -$8.24 | -$2.16 | -$6.66 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$116.8 | -$83.84 | -$69.2 | -$52.89 |
| Operating activities | ||||
| Depreciation | $3.55 | $2.81 | $1 | $1.12 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $17.09 | $11.26 | $9.95 | $8.69 |
| Total cash flows from operations | -$97.05 | -$70.77 | -$61.03 | -$40.49 |
| Investing activities | ||||
| Capital expenditures | -$1.13 | -$0.84 | -$0.76 | -$0.4 |
| Investments | $105.26 | -$44.65 | -$80.59 | -$87.04 |
| Total cash flows from investing | $104.13 | -$45.49 | -$81.35 | -$87.44 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.45 | $131.18 | $141.48 | $75.46 |
| Net borrowings | ||||
| Total cash flows from financing | $1.45 | $131.18 | $141.48 | $75.46 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $8.53 | $14.92 | -$0.89 | -$52.47 |
News
Fundamentals
| Market cap | $1.03B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 34.90M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.18 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 9.90 |
| Quick ratio | N/A |